1240038-58-7

Basic information

• Product Name: (S)-2-cyano-N-(1-phenylbutyl)acetamide
• Synonyms: (S)-2-cyano-N-(1-phenylbutyl)acetamide
• CAS NO: 1240038-58-7
• Molecular Weight: 216.283
• Mol File: 1240038-58-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (S)-2-cyano-N-(1-phenylbutyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-cyano-N-(1-phenylbutyl)acetamide(1240038-58-7)
• EPA Substance Registry System: (S)-2-cyano-N-(1-phenylbutyl)acetamide(1240038-58-7)

Safety Data

• Hazardous Substances Data: 1240038-58-7(Hazardous Substances Data)

Upstream product

• 3789-60-4 (S)-1-amino-1-phenylbutane 
• 372-09-8 cyanoacetic acid 
• 36140-83-7 1-cyanoacetyl-3,5-dimethylpyrazole 
• 105-34-0 methyl 2-cyanoacetate 

Downstream Products

• 1001088-84-1 (S,E)-3-(2-chloro-6-nitrophenyl)-2-cyano-N-(1-phenylbutyl)acrylamide 
• 1001088-87-4 (S,E)-3-(3-bromo-4-hydroxyphenyl)-2-cyano-N-(1-phenylbutyl)acrylamide 
• 1001088-79-4 (S,E)-2-cyano-3-(4-nitrophenyl)-N-(1-phenylbutyl)acrylamide 
• 856243-80-6 WP 1130 
• 1567834-38-1 C₃₃H₃₃N₅O₂ 

Relevant articles and documents

Degrasyn exhibits antibiotic activity against multi-resistant: Staphylococcus aureus by modifying several essential cysteines

Degrasyn inhibits deubiquitination enzymes and has anti-cancer activity. We here show that it also exhibits antimicrobial activity against multi-resistant Staphylococcus aureus. Structure activity relationship studies demonstrate an important role of the

Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)

A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines. The lead compounds T5165804 and CP2005 showed higher nanomolar potency against the

Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma

With the goal of developing small molecules as novel regulators of signal transduction and apoptosis, a series of tyrphostin-like compounds were synthesized and screened for their activity against MM-1 (multiple myeloma) cells and other cell lines representing this malignancy. Synthesis was completed in solution-phase initially and then adopted to solid-phase for generating a more diverse set of compounds. A positive correlation was noted between compounds capable of inducing apoptosis and their modulation of protein ubiquitination. Further analysis suggested that ubiquitin modulation occurs through inhibition of cellular deubiquitinase activity. Bulky groups on the sidechain near the α,β-unsaturated ketone caused a complete loss of activity, whereas cyclization on the opposite side was tolerated. Theoretical calculations at the B3LYP/LACV3P** level were completed on each molecule, and the resulting molecular orbitals and Fukui reactivity values for Cβ carbon were utilized in developing a model to explain the compound activity.